Cannabis

Recent articles

A photograph of a scientist holding a cannabis plant

Cannabis may be rescheduled–what does it mean for neuroscience?

The drug could become much easier to access, increasing the number of researchers who can work with it and the manufacturers who can produce it.

By Gina Jiménez
22 May 2024 | 6 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

How organ-on-a-chip models can help drug development

This month’s Going on Trial newsletter explores how organ-on-a-chip models could smooth the transition from preclinical to clinical trials, among other drug development news.

By Calli McMurray
31 July 2023 | 5 min read
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Prenatal exposures; Angelman trial suspension; autistic adult well-being

This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.

By Emily Harris
17 July 2023 | 4 min read
Research image of cultured neurons.
Epilepsy Microphone

Cannabis compound rebalances signaling to quell seizures in mice

Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.

By Peter Hess
22 March 2023 | 5 min listen

Explore more from The Transmitter

Cell population in brainstem coordinates cough, new study shows

The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.

By Calli McMurray
6 September 2024 | 5 min read
Capitol building
Spectrum Microphone

In updated U.S. autism bill, Congress calls for funding boost, expanded scope

The current Autism CARES Act sunsets in late September.

By Rachel Zamzow
5 September 2024 | 5 min listen
Illustration of ketamine blocking open ion channels in active NMDA receptors, quieting the cells and disrupting downstream signaling involved in depression.

Ketamine targets lateral habenula, setting off cascade of antidepressant effects

The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.

By Olivia Gieger
4 September 2024 | 6 min read